Mianserin
- Generic Name
- Mianserin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H20N2
- CAS Number
- 24219-97-4
- Unique Ingredient Identifier
- 250PJI13LM
- Background
A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
- Indication
For the treatment of depression.
- Associated Conditions
- Depression
A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Zhenghui YI
- Target Recruit Count
- 300
- Registration Number
- NCT05599126
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Treatment of Sleep Disturbances in Trauma-affected Refugees
Phase 4
Completed
- Conditions
- Post Traumatic Stress DisorderDepression
- Interventions
- Behavioral: Imagery Rehearsal Therapy
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Mental Health Services in the Capital Region, Denmark
- Target Recruit Count
- 241
- Registration Number
- NCT02761161
- Locations
- 🇩🇰
Competence Centre for Transcultural Psychiatry, Copenhagen, Ballerup, Denmark
Pharmacovigilance in Gerontopsychiatric Patients
Phase 3
Terminated
- Conditions
- DementiaDepressionSchizophreniaPsychosomatic DisordersAnxiety Disorders
- Interventions
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 407
- Registration Number
- NCT02374567
- Locations
- 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪Hannover Medical School, Hannover, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath